Despite a lack of in vivo efficacy of the chosen drug combination, genetic WEE1 KD in an in vivo PDX model led to reduction of tumor growth, as well as increased survival of immune-deficient mice, proving WEE1 as a promising target in LFS-associated SHH-MB. This evidence concerns the gene WEE1 and neoplasm.